Drilldown: Medicines

Asenapine (1) · Brivaracetam (1) · Cannabidiol (1) · Cenobamate (1) · Chlorpromazine (1) · Citalopram (1) · Clobazam (1) · Clozapine (1) · Droperidol (1) · Escitalopram (1) · Eslicarbazepine (1) · Ethosuximide (1) · Felbamate (1) · Fenfluramine (1) · Fluphenazine (1) · Fluvoxamine (maleate) (1) · Fosphenytoin (1) · Iloperidone (1) · Lacosamide (1) · Loxapine (1) · Lurasidone (1) · Molindone (1) · Paliperidone (1) · Paroxetine (HCl; mesylate as Pexeva) (1) · Perampanel (1) · Perphenazine (1) · Phenobarbital (1) · Phenytoin (1) · Pimozide (1) · Rufinamide (1) · Stiripentol (1) · Thioridazine (1) · Thiothixene (1) · Tiagabine (1) · Trifluoperazine (1) · Valproic acid (1) · Vigabatrin (1) · Ziprasidone (1) · Zonisamide (1)

Aptiom (1) · Banzel (1) · Briviact (1) · Celexa (1) · Cerebyx (1) · Clozaril (1) · Depakote (1) · Diacomit (1) · Dilantin (1) · Epidiolex (1) · Fanapt (1) · Felbatol (1) · Fintepla (1) · Fycompa (1) · Gabitril (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Lexapro (1) · Loxitane (1) · Luminal (1) · Luvox (US brand discontinued; generic widely available), Luvox CR, Faverin (other markets) (1) · Mellaril (1) · Moban (1) · Navane (1) · Onfi (1) · Orap (1) · Paxil (IR), Paxil CR (controlled-release), Brisdelle (low-dose for menopausal vasomotor symptoms), Pexeva (paroxetine mesylate) (1) · Prolixin (1) · Sabril (1) · Saphris (1) · Stelazine (1) · Thorazine (1) · Trilafon (1) · Vimpat (1) · Xcopri (1) · Zarontin (1) · Zonegran (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (2) · AMPA receptor antagonist (1) · Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) · GABA reuptake inhibitor (GAT-1 blocker) (1) · GABAA positive allosteric modulator (1) · GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) · GABAA potentiator and direct activator (1) · Irreversible GABA-T inhibitor (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) · NMDA antagonist; GABAA potentiator (1) · Phenothiazine D2 antagonist (4) · Prodrug of phenytoin; sodium channel blocker (1) · Serotonin releaser; sigma-1 agonist (1) · Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) · Sodium channel blocker (2) · Sodium channel blocker; GABAA positive allosteric modulator (1) · Sodium channel modulator (1) · Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) · SV2A ligand (higher affinity than levetiracetam) (1) · T-type calcium channel blocker (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-0000001D-QINU`"' CYP2C19 + CYP3A4 metabolism, with CPIC PGx guidance: poor CYP2C19 metabolizers have ~3-fold higher exposure and benefit from a lower starting dose; ultrarapid metabolizers may have inadequate response'"`UNIQ--ref-0000001E-QINU`"'. (2)

None (35) · '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"' (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2) · '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"', '"`UNIQ--vote-00000029-QINU`"', '"`UNIQ--vote-0000002A-QINU`"' (1)

None (35) · 10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed (1) · 20 mg PO once daily; titrate to 40 mg/day after 1 week if tolerated. Elderly (>60) and hepatic impairment: 20 mg/day ceiling (1) · 50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day (1) · MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes (1)

None (35) · IR tablets 10, 20, 30, 40 mg; CR tablets 12.5, 25, 37.5 mg; oral suspension 10 mg/5 mL; Brisdelle capsules 7.5 mg (1) · IR tablets 25, 50, 100 mg; Luvox CR capsules 100, 150 mg (1) · Tablets 10, 20, 40 mg; oral solution 10 mg/5 mL (1) · Tablets 5, 10, 20 mg; oral solution 1 mg/mL (1)

None (35) · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60 (1) · 20 mg/day (adult); 10 mg/day in elderly and in hepatic impairment (1) · 300 mg/day (IR or CR) (1) · 50 mg/day (IR); 62.5 mg/day (CR); 60 mg/day (OCD) (1)

None (35) · Oral (4)

None (35) · Antidepressant effect emerges over 1-2 weeks (1) · Antidepressant effect emerges over 1-2 weeks; full clinical effect 4-6 weeks (1) · Antidepressant effect over 1-2 weeks; full clinical effect 4-6 weeks (1) · OCD effect over 1-2 weeks initial, with full effect typically 6-12 weeks; among the slowest SSRIs for OCD response (1)

None (35) · 24 hours (once-daily dosing) (3) · BID at higher doses (IR); once-daily (CR) (1)

None (35) · 27-32 hours'"`UNIQ--ref-00000026-QINU`"' (1) · ~15 hours (IR)'"`UNIQ--ref-00000023-QINU`"' (1) · ~21 hours (with nonlinear pharmacokinetics from CYP2D6 autoinhibition)'"`UNIQ--ref-0000002B-QINU`"' (1) · ~35 hours'"`UNIQ--ref-00000026-QINU`"' (1)

None (35) · Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"' (1) · ~53% (oral)'"`UNIQ--ref-00000024-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (2)

None (36) · '''Among the least preferred SSRIs in pregnancy.''' Observational signal for cardiac malformations (atrial and ventricular septal defects) with first-trimester exposure, and the most severe neonatal adaptation syndrome of any SSRI with third-trimester exposure'"`UNIQ--ref-0000002D-QINU`"' (1) · Observational signal for neonatal adaptation syndrome with third-trimester exposure (SSRI class effect).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Observational signal for persistent pulmonary hypertension of the newborn (small absolute risk) and neonatal adaptation syndrome with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (35) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000025-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000028-QINU`"' (2) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000002E-QINU`"' (1)